{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:01:30Z","timestamp":1790492490532,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Oral vancomycin (OV) has limited usage in paediatric inflammatory bowel disease (PIBD) with reported efficacy in primary sclerosing cholangitis (PSC\u2010PIBD), acute severe colitis as part of quadruple\u2010antibiotic regimen, and very early\u2010onset IBD. This study evaluates OV effectiveness and safety as a single\u2010agent in non\u2010PSC PIBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single\u2010centre retrospective study included patients on OV for active disease or steroid\/topical therapy dependency. Exclusion criteria were PSC diagnosis,\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection, induction treatment started &lt;3 weeks prior, and OV as part of quadruple\u2010antibiotic regimen. Disease activity was assessed at baseline, 1\u2010, 3\u2010, 6\u2010 and 12\u2010months. OV was started at 250\/125\u2009mg (\u226530\/&lt;30\u2009kg), three or four times daily, and tapered in responders after \u22651 month.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010one patients (16 males; median age 15.1 years, IQR:11.7\u201316.6) were included: 23 ulcerative colitis (UC), 4 IBD\u2010unclassified (IBDU) and 4 Crohn's disease. OV dosing was 17.5\u2009mg\/kg\/day (IQR: 15.3\u201321.6) for 4 months (IQR: 1\u20139). Clinical and biochemical remission was achieved or maintained in 17\/31 (55%), with 15\/17 reducing\/stopping other treatments and two remaining on OV monotherapy. Conversely, 14\/31 (45%) discontinued OV due to non\u2010response (11\/14) or intolerance (3\/14), the majority (11\/14) within 1 month. Responders had lower baseline clinical disease activity and platelet count (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). At 1\u2010month faecal calprotectin dropped from 686 to 60\u2009\u03bcg\/g in responders (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) but remained high in nonresponders. No serious adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OV was rapidly effective in 55% of PIBD cases, enabling 48% to reduce or stop other treatments. It proved most beneficial in mildly active UC\/IBDU as an induction strategy plus a maintenance option for some, with a role in others in treatment de\u2010escalation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70180","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:34:37Z","timestamp":1754451277000},"page":"1416-1426","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of oral vancomycin in non\u2010primary sclerosing cholangitis paediatric inflammatory bowel disease"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7690-8369","authenticated-orcid":false,"given":"Silvana","family":"Ancona","sequence":"first","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gianolio","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"},{"name":"Department of Paediatrics, Vittore Buzzi Children's Hospital University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Rabone","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Merrick","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"},{"name":"Child Life and Health University of Edinburgh Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"},{"name":"Child Life and Health University of Edinburgh Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-4926","authenticated-orcid":false,"given":"Richard K.","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Children and Young People Edinburgh UK"},{"name":"Child Life and Health University of Edinburgh Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002908"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.136"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i21.3306"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.72"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13905"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315199"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12430"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17936"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae257"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241312766"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475660"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.12.1380"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz298"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21493"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20867"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21649"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otz015"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001605"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2010.544671"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","unstructured":"AntoonJW HallM MetropulosD et al.Clinical Investigation A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis;2016.","DOI":"10.5863\/1551-6776-21.5.426"},{"key":"e_1_2_8_23_1","unstructured":"Strides Pharma UK Ltd.Vancomycin 125 mg Hard Capsules [Summary of Product Characteristics]. Electronic Medicines Compendium; 2022.https:\/\/www.medicines.org.uk\/emc\/product\/14317\/smpc#gref"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231156761"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/idr15020019"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.48.7.689-b"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47701"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2010.513066"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1538"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800505"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf006"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae189"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12378"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1787501"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000577"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S186097"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(96)00156-7"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9801-1"},{"issue":"4","key":"e_1_2_8_39_1","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"4","author":"Imdad A","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11051272"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2018_319"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-022-01286-9"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251332453"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70180","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70180","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:22:29Z","timestamp":1780629749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/jpn3.70180"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70180","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}